Astral Systems, a deeptech company pioneering multi-state fusion (MSF) technology, has secured a £23 million first close investment led by Mercia Ventures. The round is supported by various investors including Tees River, Daphni, and Blast Club, alongside previous investors Speedinvest and Playfair.
The raise brings the company’s funding of Astral Systems to over £28 million.
Astral Systems is turning breakthrough physics into a new class of commercially viable fusion technology with near-term applications. It aims to tackle the fragile supply chain and potential global shortages of medical radioisotopes that severely impact cancer diagnosis and treatments. This includes bringing critical medical isotopes to market by early 2027, scaling the production of its modular MSF reactors, and advancing fusion research.
Unlike traditional fusion ventures focused solely on long-term power generation, Astral Systems has multiple Technology Readiness Level 9 (TRL9) fusion reactors operational today. These compact multi-state fusion reactors achieve unmatched performance with greater efficiency and lower cost than traditional configurations.
Over the following years, Astral Systems intends to manufacture dozens more reactors as it expands the applications of its multi-state fusion technology across commercial sectors.
